Visual Fields at School-Age in Children Treated with Vigabatrin in Infancy. Gaily E, Jonsson H, Lappi M. Epilepsia 2009;50(2):206-216. PURPOSE: The use of vigabatrin (VGB) as an antiepileptic drug (AED) has been limited by evidence showing that it causes vigabatrin-attributed visual field loss (VAVFL) in at least 20-40% of patients exposed at school age or later. VGB is an effective drug for infantile spasms, but there are no reports on later visual field testing after such treatment. Our aim was to investigate the risk of VAVFL in school-age children who had received VGB in infancy. METHODS: Visual fields of 16 children treated with VGB for infantile spasms were examined by Goldmann kinetic perimetry at age 6-12 years. Normal fields were defined as the temporal meridian extending to more than 70 • , and mild VAVFL between 50 and 70 • . Abnormal findings were always confirmed by repeating the test.
peripheral visual field deficits who are withdrawn from vigabatrin do not show improvement in their visual fields. Until now, however, little was known about the possibilities of ophthalmological damage in infants and young children-the study by Gaily et al. fills this knowledge gap. Although a small study, all the children (n = 16) were treated for infantile spasms with vigabatrin, and the automated visual fields assessments were performed as soon as the children were old enough to be able to cooperate. The studies were carried out after at least 4 years on vigabatrin and are encouraging, as only one child had a slight peripheral visual field deficit and 15 others tested normal.
There is an important historical lesson regarding visual field deficits in humans: at the time vigabatrin was new and undergoing clinical trials, the FDA was the most skeptical of the agencies involved in assessing the drug, especially when it was realized that vigabatrin first, could cause retinopathy in rats and then that it was associated with reversible intramyelinic edema in the brains of rodents and dogs but not of monkeys (4) . After extensive testing of patients in clinical trials and from autopsy reports, the intramyelinic edema concern for humans was laid to rest (2) . Next, just when the FDA was reconsidering approving vigabatrin in the 1990s, the first confirmed reports of visual field deficits appeared. Now, 12 years later, vigabatrin has been exhumed in the United States, as the FDA again is deciding if it should be made available. On the heels of the FDA review, new articles about long-term vigabatrin use are being published in an attempt to better understand and calculate its risks and benefits. In other countries throughout the world, vigabatrin has proven to be an invaluable and effective treatment for infantile spasms (5) . Very few side effects are reported among children, and vigabatrin seems to be extremely well tolerated in this patient population. Aware of this favorable profile, most pediatric neurologists in the United States await with enthusiasm the pending approval of vigabatrin.
Vigabatrin is an irreversible GABA-transaminase inhibitor and can increase whole GABA in the brain by 300% in a predictable, dose-response manner (6) . There has never been another mechanism of action found for this drug that is of significance. Therefore, vigabatrin for the most part is considered to be a disease-specific compound, as GABA is an inhibitory neurotransmitter that is effective in inhibiting excitatory reactions, such as seizures (7) .
How does vigabatrin cause peripheral visual field deficits? The retina is not protected by the blood-brain barrier, and 10% of vigabatrin in the blood will pass through the blood brain barrier to the brain (8) . Far greater amounts of the drug are able to enter the retina, which has no significant barriers for vigabatrin; thus, vigabatrin and subsequent GABA levels are even higher in the ocular region. The most viable hypothesis to date, however, is that it is not GABA itself that affects the cones of the retina, but rather vigabatrin. One study showed that when the retina is exposed to light, vigabatrin reacts to cause retinopathy-at least in rats (9) . However, it has not been shown that the retinopathy in rats is the same as peripheral visual field deficits found in humans.
There may be several reasons why infants do not develop visual field deficits. Although the cause is not definitively known, developmental differences in cones (most affected in animals) and the specific stage of development of the optic nerve may prevent the deficits in infants. In addition, small children are not exposed to bright lights as often as older children and adults, which may impact the incidence. Yet, even in adult patients with partial onset seizures, for whom vigabatrin may be an effective last resort treatment, the total amount of vigabatrin ever taken is the most important factor in development of visual field deficits. Thus, one treatment strategy would be to treat a patient for 6 months, evaluate for efficacy, and if there is no beneficial effect, stop the treatment. If treatment is effective, continue it, while every 3-6 months closely monitor the visual fields with automated perimetry and discuss with the patient whether or not to carry on. The Gaily et al. study is valuable in demonstrating that the risk of field deficits is not as great for children as for adults; thus, therapy can be started in infants with minimal risk. However, as noted, therapy for infants needs to be continually reevaluated and attempts to stop the drug should be made after a year or so of successful therapy.
What does previous and current MRI analysis tell us about intramyelinic edema? Until recently, the changes in the intramyelinic edema and microvacuolization were not known to occur in humans. Because of the existence of intramyelinic edema in rodents and dogs, many MRI studies were done with patients who participated in the previous clinical trials (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) , but no pathology was ever found (10) . The first publication of intramyelinic edema and microvacuolization MRI changes in humans was in the form of an abstract, and a complete report was published in 2009 (11) . The abnormalities were picked up by T 2 -weighted MRIs, with increased signals on diffusion-weighted imaging (DWI) and fluid-attenuated inversion-recovery (FLAIR) studies. These studies were retrospective, with no control group, and the link between vigabatrin and intramyelinic edema on MRI still could not be firmly established.
The study by Wheless and colleagues presents the data of all known cases of suspect intramyelinic edema associated with vigabatrin-treated patients (mostly infantile spasms) as well as a review of all previous studies using MRI for children and adults. The analysis from this review suggests that intramyelinic edema and microvacuolization changes do occur in the immature brain but not that of older children and adults. The mechanisms underlying this finding are unknown, but the changes seem to be largely reversible whether or not the drug is stopped. One speculation is that is the harmful effects are caused by GABAergic neurotoxicity (12) . The clinical consequences also are unknown, although many infants have been treated with vigabatrin without unusual events. However, these children often have other serious comorbidities, and it is unclear if any of the mental or physical disabilities are associated in any way with intramyelinic edema, as the clinical causes and associations could be hidden in the plethora of their disabilities and not be determined. Only a long-term prospective, placebo-controlled study of infants being treated with vigabatrin that uses MRI for the clinical assessment can answer this question (a study that the authors do suggest).
So, should infants be offered vigabatrin when faced with intractable infantile spasms? Maybe. However, it does seem unethical not to offer a chance at seizure freedom from this catastrophic form of epilepsy, which likely is equated with nonconvulsive status epilepticus. A solution to the concern about prescribing vigabatrin could be to closely study all infants, follow the clinical efficacy, side effects, and MRI, and act immediately to cease the drug if T 2 abnormalities appear that were not present at baseline. The benefits of seizure freedom in these children may outweigh the unknown risks of reversible intramyelinic edema, but it is also important not to continue treatment when vigabatrin does not rapidly achieve a beneficial effect.
The controversy with vigabatrin continues, as it is a drug with excellent efficacy but unusual and disturbing side effects, which have limited its use for the last 12 years. Hopefully, the information gained from these two articles as well as by other recent studies on vigabatrin toxicity will shed some light on how it can still be used without causing harm, but rather only benefit, to the patient. Among these, 87% were taking two or more concomitant AEDs. Median percent reduction in seizure frequency per 28 days from baseline to maintenance period (intent-to-treat, ITT) was 20.5% for placebo, 35.3% for lacosamide 200 mg/day (p = 0.02), and 36.4% for 400 mg/day (p = 0.03). In the per protocol population, the reductions were 35.3% for lacosamide 200 mg/day (p = 0.04) and 44.9% for 400 mg/day ( p = 0.01) compared to placebo (25.4%). The 50% responder rate for lacosamide 400 mg/day (40.5%) was significant ( p = 0.01) over placebo (25.8%), but was not for 200 mg/day (35.0%). In the per protocol population, the 50% responder rate for 
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L acosamide was recently approved as an antiepileptic drug for adjunctive therapy of partial onset seizures in the United States and the European Union. Lacosamide's most clinically relevant mechanism appears to be the enhancement of slow inactivation of voltage-gated sodium channels (1); thus, the mechanism is reportedly different from the sodium channel effect of phenytoin and carbamazepine, which enhance the fast inactivation of voltage-gated sodium channels (2) . Although this characteristic appears to make lacosamide somewhat unique, the clinical implications of the mechanistic differences are unknown. Lacosamide is rapidly and completely absorbed, has a half-life of 13 hours, and demonstrates linear kinetics in the dose range of 100-800 mg. Ninety-five percent of the drug is eliminated in the urine, 40% unchanged. The major metabolic pathway is demethylation, which is dependent on cytochrome P450 CYP2C19. Inducers of P450 CYP2C19 would be expected to increase lacosamide metabolism, but preliminary data failed to show an effect of carbamazepine and phenytoin on lacosamide plasma concentrations (2). Lacosamide does not induce or inhibit cytochrome P450 enzymes and is unlikely to have clinically significant interactions when added to other medications (3). A low protein binding of less than 15% is another feature that reduces the potential for interaction.
In a previous study by Ben-Menachem and colleagues, efficacy of lacosamide as an adjunctive therapy was examined at three doses, 200, 400, and 600 mg/day, administered twice daily (4). The two higher doses were significantly better than placebo in reducing seizure frequency. The dose of 200 mg/day was superior to placebo in decreasing seizure frequency for the "per protocol" population, but the difference did not reach significance in the intent-to-treat analysis. The responder rates were very similar in the current study by Halász et al. when compared with the prior Ben-Menachem et al. study, with approximately 40% responder rate at the 400 mg/day dose and 33 to 35 percent responder rate at the 200 mg/day dose. The median percent seizure reduction for 200 mg/day was slightly higher (35.3%) in the Halász et al. study in comparison with the earlier study (26%), but there was also a greater median percent seizure reduction in the placebo group (20.5% vs 10%). The study by Halász and colleagues confirmed efficacy for the 400-mg/day dose and found that while the 200-mg/day dose was superior to placebo in seizure reduction, it was not significantly better than placebo in 50% responder rate. However, a pooled analysis of the two studies found that 200 mg/day was significantly better than placebo in both the median percent in seizure reduction and the 50% responder rate (2). The pooled analysis was even able to demonstrate that lacosamide was superior to placebo in reducing seizure frequency at a dose of 100 mg/day during titration.
A dose of 600 mg/day was not included in the current study by Halász et al. but was evaluated in a third study by Chung et al., which was published only in abstract form (5) . The Chung Epilepsy Currents, Vol. 9, No. 5 (September/October) 2009 pp. 133-134 Wiley Periodicals, Inc. C American Epilepsy Society et al. study compared 400 mg and 600 mg of lacosamide to placebo in a patient population that is very similar to that in the study by Halász et al. Both doses were superior to placebo and close to each other in efficacy measures, with around 37 to 38 percent seizure reduction and 38 to 41 percent responder rates. In general, the 600-mg/day dose was not significantly better than 400 mg/day either in seizure reduction or the 50% responder rate, but it was associated with a greater incidence of adverse effects. As a result, both European and U.S. regulatory agencies approved lacosamide at doses of 200 and 400 mg/day. Nevertheless, individual patients may tolerate and benefit from a higher dose.
With respect to seizure freedom, which is the ultimate target of any epilepsy therapy, 3.6% and 2.4% of patients who completed the maintenance period were seizure-free at the 200mg and 400-mg daily doses, with 2.1% of placebo patients also seizure-free in the Halász et al. study. In the previous published study by Ben-Menachem et al., 0%, 1.2%, 6.2%, and 1.6% of patients who completed the study were seizure-free with placebo, 200, 400, and 600 mg/day of lacosamide, respectively (4), The seizure-free numbers were 0%, 2.5%, and 8.1% for placebo, 400, and 600 mg/day, respectively, in the third study by Chung et al. (5) .
The most common adverse effects were fairly consistent between the Halász et al. and Ben-Menachem et al. lacosamide trials. The adverse experiences of dizziness, headache, and nausea were noted in both published studies, but the most common adverse experience, dizziness, occurred less frequently in the Halász et al. study-10.4% at 200 mg/day and 15.7% at 400 mg/day, as compared with 24% and 26%, respectively, in the Ben-Menachem et al. study. Similarly, there was a lower incidence of other less common adverse experiences in the current study. The reason for this finding is unclear, and it is not known if doses of concomitant antiepileptic drugs were lower in the study by Halász and colleagues in comparison to the previous study.
Lacosamide will be an important addition for patients with refractory partial epilepsy. However, it is not totally clear where lacosamide will be positioned for the treatment of partial epilepsy, in general. The choice of an antiepileptic drug is dependent on many factors, including safety, efficacy, tolerability, ease of use and titration, as well as usefulness in treating comorbidities. Lacosamide appeared safe in the pivotal trials, but comfort with safety requires exposure of a large number of individuals, as may occur in the first year of use. Efficacy, tolerability, and ease of use and titration have been demonstrated in the existing lacosamide trials. The availability of an intravenous formulation is another desirable feature of lacosamide shared by only a handful of antiepileptic drugs. With respect to comorbidities, lacosamide has no indications outside of partial epilepsy, but there are data supporting its efficacy in painful diabetic neuropathy (6) (7) (8) . Thus, it may be a drug that could be considered at an earlier stage for epilepsy patients who have this comorbidity. At present, lacosamide is approved only for adjunctive use, making interactions with other antiepileptic drugs an important consideration. No clinically significant pharmacokinetic interactions have been demonstrated, but the existing trial data should be examined for evidence of pharmacodynamic interactions with antiepileptic drugs (e.g., carbamazepine) that act on the sodium channel. The lacosamide adverse effects of dizziness, nausea, ataxia, and diplopia are shared with various sodium-channel-blocking medications, which were the most common concomitant antiepileptic drugs used in these trials. Analysis of adverse experiences in relationship to concomitant antiepileptic drugs may help identify such interaction. Interactions are not a factor when an agent is used as monotherapy; accordingly, a monotherapy trial of lacosamide is currently under way. If this trial demonstrates lacosamide monotherapy efficacy, it will greatly enhance its place in epilepsy therapy. 
T he association between epilepsy and psychiatric disorders is well established (1-3). Mood and anxiety disorders have been reported in up to 50% of patients with epilepsy (4), while psychotic disorders are less frequent but higher than in the general population (5) . Psychiatric disorders tend to be viewed as a common comorbidity of epilepsy; although often underdiagnosed, they are important to recognize, potentially exacerbated by or concomitantly treated with antiepileptic medications (6) , and contribute to a worsened quality of life (7) . However, the relationship between psychiatric disorders and epilepsy has been shown to be bidirectional-each independently increases the risk of developing the other (8) . As such, it is intriguing to consider that both epilepsy and psychiatric disorders also may modify the outcome of the other.
The observation that therapeutic control of psychiatric and epileptic disorders is correlated initially was addressed in a postsurgical study in 1963. Examining a large group of patients who underwent temporal lobectomy, Falconer et al. demonstrated that postoperative improvements in seizure control corresponded to improvements in the psychiatric domain (9) . It is interesting to note that these surgical patients were largely identified from a psychiatric hospital and most had a preoperative psychiatric disorder. Subsequent studies of postoperative cohorts from epilepsy practices have demonstrated increases in psychiatric symptoms postoperatively (particularly shortly after surgery) that are independent of seizure control (10, 11) .
More recently, the presence or absence of a psychiatric disorder has been identified as a predictor of a worse outcome in epilepsy (12) , especially as a predictor of postsurgical seizure outcome, as illustrated herein by Kanner et al. The study center was uniquely qualified to perform this trial, as all presurgical patients undergo a semistructured interview, based on the Structured Clinical Interview for DSM IV disorders. In this retrospective study of 100 consecutive patients who underwent anterior temporal lobectomy (ATL), the authors examined the lifetime psychiatric history, age of onset and duration of epilepsy, extent of surgical resection, and Engel class seizure outcomes. Patients generally remained on at least one AED indefinitely following surgery. Fifty-six percent of the subjects had a presurgical lifetime history of a psychiatric disorder, consistent with the high prevalence reported in other studies (1) (2) (3) (4) . Mood and anxiety disorders accounted for most of the psychiatric history. Two years after the surgery, 44% of the subjects in the cohort were taking a psychotropic drug-a sobering statistic. The use of psychotropic medications postsurgically was not associated with seizure outcome.
The study's findings reflect the theme that psychiatric disorders and epilepsy outcome are concordant. The absence of a lifetime history of psychiatric illness strongly predicted a class 1A (i.e., no seizures, no auras) postsurgical outcome. In fact, those without a psychiatric history were 13 times more likely to have a class 1A outcome than those with a lifetime history of psychiatric illness. When assessing class 1A and class 1B (i.e., only auras but no disabling seizures) together, patients without Epilepsy Currents, Vol. 9, No. 5 (September/October) 2009 pp. 135-136 Wiley Periodicals, Inc. C American Epilepsy Society a history of psychiatric disorders were seven times more likely to experience this outcome. The effect of an absence of psychiatric illness was the most predictive when considering classes 1A, 1B, and IC (i.e., disabling seizures caused by medication discontinuation or having had up to 3 disabling seizures during the first postsurgical year only) together, as patients without a history of psychiatric disorder were 16 times more likely to have a favorable outcome than those with the presence of a psychiatric history. Other nonpsychiatric factors also were associated with favorable seizure outcomes, including a larger resection of mesial structures, presence of mesial temporal sclerosis (MTS), and absence of a presurgical history of generalized tonic-clonic seizures.
There is other evidence that the presence of psychiatric disorders is associated with worse seizure outcomes, both medical and surgical. In a large cohort of subjects with newly diagnosed epilepsy, a history of psychiatric comorbidity was associated with progression to refractory disease (12) . In another study, which examined postsurgical temporal lobectomy patients, a past psychiatric history plus new postsurgical psychiatric symptomatology predicted poor seizure outcome (10) . Interestingly, although epilepsy surgery is associated with a high prevalence of postsurgical psychiatric symptomatology, a past history of psychiatric disorders does not seem to predict postsurgical psychiatric symptoms (10) .
Why are psychiatric history and postsurgical seizure outcome related? As the authors discuss, the mechanisms remain largely unknown, despite ample evidence for common pathologic mechanisms in epilepsy and depression. Perhaps, mood disorders are a marker for a more extensively damaged cortex (i.e., a larger or more diffuse epileptogenic zone). It is also important to consider the possibility of nonepileptic seizures, particularly as postoperative anxiety disorders may mimic seizures. This effect was accounted for in the current study, as all patients who experienced more than three seizures postsurgically underwent video-EEG monitoring to rule out the possibility of postsurgical nonepileptic seizures.
Since the publication of the paper by Kanner and colleagues, similar findings have been reported, highlighting the increasing interest in and recognition of the importance of comorbid psychiatric disorders and epilepsy surgery (13) . What do these findings mean to the clinician? Clearly, it is critical to recognize the need to systematically and thoroughly explore the psychiatric history of all patients with epilepsy, particularly those individuals considering epilepsy surgery. While such a history should not prevent a temporal lobectomy, the possibility that psychiatric disorders may be a marker for a more extensive epileptogenic zone should be considered during the presurgical evaluation, and there may as well be potential implications for presurgical counseling and postsurgical medication decisions.
A number of additional issues that remain to be explored, including outcomes of epilepsy surgeries other than temporal lobectomy and the potential contribution of laterality, were not addressed by Kanner et al. Overall, however, the results of this and similar studies demonstrate the need for greater rigor in the psychiatric assessment of presurgical patients with epilepsy. [ p = 0.028; OR of contralateral spread versus no spread = 2.591; 95% CI = (1.112, 6.039)] and gender [ p = 0.048; OR of female versus male = 0.422; 95% CI = (0.179, 0.994)]. In the subset of 253 partial seizures without secondary generalized convulsions, 34.8% of seizures had desaturations below 90%, 31.8% had desaturations below 80% and 12.5% had desaturations below 70%. The degree of desaturation was significantly correlated with seizure duration (p = 0.001) and with electrographic evidence of seizure spread to the contralateral hemisphere (p = 0.003). Central apnoeas or hypopnoeas occurred with 50% of 100 seizures. Mixed or obstructive apnoeas occurred with 9% of these seizures. End-tidal carbon dioxide (ETCO2) was recorded in seven patients (19 seizures). The mean increase in ETCO2 from preictal baseline was 18.6 ± 17.7 mm Hg (13.2; 2.8-77.8). In these 19 seizures, all oxygen desaturations below 85% were accompanied by an increase in ETCO2. Ictal hypoxemia occurs often in patients with localization-related epilepsy and may be pronounced and prolonged; even with seizures that do not progress to generalized convulsions. Oxygen desaturations are accompanied by increases in ETCO2, supporting the assumption that ictal oxygen desaturation is a consequence of hypoventilation.
Ictal hypoxemia and hypercapnia may contribute to SUDEP. COMMENTARY S udden unexpected (or unexplained) death in epilepsy (SUDEP) occurs at a rate of approximately 1 in 1,000 person-years, when combining all epilepsy types and severities, and increases to 1 in 150 person-years for those with refractory epilepsy (1, 2) . The vast majority of SUDEP deaths are associated with seizures. Young adults with uncontrolled convulsive seizures constitute the highest risk group, though SUDEP occurs in many other patient populations. Leading theories of the cause of SUDEP include ictal or postictal cardiac arrhythmias, apnea (central apnea is more commonly invoked than obstructive apnea, though both might play a role), and cerebral shutdown, with flattening of the EEG that never recovers (1, 3, 4) . Although there have been many publications on the cardiac effects of seizures, effects on oxygenation and respiration have received minimal investigation. Yet, among six cases of SUDEP or near-SUDEP (i.e., cardiopulmonary arrest with successful resuscitation) that occurred during EEG monitoring, arrhyth-mia was only documented in one patient and that patient had a prior myocardial infarction (1) . Three of the other five cases were felt to be due to "central nervous system shutdown," one to central apnea, and one to obstructive apnea, possibly laryngeal spasm. Of note, none of these cases had oxygen saturation or respirations monitored, as such monitoring is not standard in most epilepsy video-EEG monitoring units-at least not yet.
In the current study by Bateman et al., continuous digital oxygen saturation was monitored during seizures in an epilepsy monitoring unit, with the results recorded second-by-second and incorporated into the video-EEG record. The investigators also continuously recorded respirations as measured by nasal airflow, respiratory effort as measured by abdominal excursions, and heart rate in 10-second epochs. The findings demonstrated conclusively that complex partial seizures, with or without generalization, commonly lead to significant and prolonged oxygen desaturation. In a subgroup of 7 patients with 19 seizures, the authors further showed that the desaturation was indeed due to hypoventilation, rather than peripheral vasoconstriction, by identifying elevated end-tidal carbon dioxide (ETCO 2 ), as averaged over 4 breaths and recorded every 4 seconds. Desaturations typically lasted more than a minute.
In some patients, hypoventilation (i.e., elevated ETCO 2 ) persisted despite increases in ventilatory rate. Overall, hypoventilation was far more commonly found to be central than obstructive. Risk factors for ictal hypoxemia included temporal lobe onset, male gender, bilateral spread, longer seizure duration, and right hemisphere onset. It is important to point out that desaturations were just as common and significant in complex partial seizures that did not progress to secondary generalized convulsions; in fact, saturation dropped below 80% in about one-third of these seizures and below 70% in one-eighth. Although this is not the first investigation documenting ictal desaturation, it is the largest and most carefully conducted study on ictal hypoventilation and hypoxemia to date.
Pertinent factors that were not associated with the risk of ictal hypoxemia included patient position at the onset of the seizure (i.e., supine, prone, sitting), antiepileptic drug load, and the degree of increase in heart rate during the seizure. An interesting observation was that O 2 saturation never dropped below 90% except in the periictal setting. This finding suggests that oximetry may be useful as a seizure detector with few false positives (high specificity, but not necessarily high sensitivity), which could be useful in both the inpatient setting and perhaps even at home or elsewhere.
As these authors and others have reviewed, respiration can be inhibited by electrical stimulation of multiple portions of the limbic system, including the hippocampus (5) . In addition, stimulation of the hippocampus has been reported to entrain the respiratory rhythm, and hippocampal activity increases just before resumption of breathing after apnea. Thus, there is some rationale for the theories that ictal activity during temporal lobe seizures can lead to apnea and that postictal limbic dysfunction might inhibit resumption of breathing. Notably, the degree of hypercarbia seen in these patients also is sufficient to affect cardiac conduction.
Bateman and colleagues found that patients with seizurerelated desaturation below 85% were highly likely to have similar desaturations with subsequent seizures. It remains to be seen if these patients are at higher risk of SUDEP and if preventing their periictal desaturations might prevent SUDEP. Animal models suggest that preventing hypoventilation or desaturation can prevent seizure-related death. For example, one study reported three strains of mice with audiogenic seizures and seizure-related sudden death in which supplying supplemental oxygen completely prevented sudden death, without affecting the seizure activity itself (6) . In addition, in a particular strain of mice (DBA/2) that have audiogenic seizures with respiratory arrest, increasing serotonin levels (via fluoxetine) prevented the ictal apnea, and most mice survived (7) . In the potentially related condition of sudden infant death syndrome (SIDS), postmortem studies have found that a large propor-tion of cases-perhaps even the majority-have an abnormality in the brainstem serotonergic system (8, 9) . This medullary 5hydroxytryptamine system is believed to be important in arousal as well as for respiratory effort and gasping, including in response to hypoxemia or hypercarbia, although several other neurotransmitters are also involved. Infants who subsequently suffer from SIDS or near-SIDS, have impaired sighs, gasps, and arousal mechanisms (9, 10) . These arousal and respiratory measures have not been studied in relation to SUDEP, though they can be easily assessed. Exposure to smoking, especially during early development, is a major risk factor for SIDS and may affect development of these arousal/respiratory pathways. Whether or not perinatal exposure to smoking is a risk factor for SUDEP is also unknown.
Investigations into respiratory drive, such as the studies of animal models or people with epilepsy discussed here, show great promise for providing clinically relevant information related to SUDEP (and SIDS), as do recent advances in the understanding of basic respiratory physiology. Programs that teach up-to-date specifics on the neuroanatomy and neurophysiology of respiration to neurologists and epileptologists would be useful as well. For example, most neurologists are not overly familiar with the pre-Botzinger complex, a component of the ventral respiratory column in the lower brainstem (11) . It is now known that the pre-Botzinger complex is critical for generating inspiration and lesioning it leads to breathing cessation (10) . Perhaps, via careful periictal monitoring of cardiac and respiratory physiology, it will soon be possible to better identify those patients at highest risk for SUDEP, the most likely mechanism(s) for it in a given individual, and a means of prevention. The potential for development of devices that can both monitor and treat the most likely mechanisms (all now technically feasible) adds further grounds for optimism in the fight against SUDEP.
Although previously SUDEP was a largely neglected condition, it is now beginning to receive the attention it deserves. The American Epilepsy Society and Epilepsy Foundation recently published a report of their Joint Task Force on SUDEP (2). The task force recommendations led to a multidisciplinary SUDEP conference, sponsored by the National Institutes of Health's National Institute of Neurological Disorders and Stroke, in which experts in cardiac death, SIDS, animal models, epidemiology, genetics, and other related disciplines participated. Whether or not the ictal hypoxemia described in this study is a major contributor to SUDEP (which it certainly might be), the collaborative approach and increased interest (and presumably, funding) points to the great potential for ultimately defining the pathophysiology of SUDEP and how to prevent it. clinical confounders. Incidence rates for serious clinical events were compared between adherent and nonadherent quarters using incidence rate ratios (IRRs) with 95% CIs calculated based on the Poisson distribution. RESULTS: The 33,658 study patients contributed 388,564 AED-treated quarters (26% nonadherent). Nonadherence was associated with an over threefold increased risk of mortality compared to adherence (hazard ratio = 3.32, 95% CI = 3.11-3.54) after multivariate adjustments. Time periods of nonadherence were also associated with a significantly higher incidence of ED visits (IRR = 1.50, 95% CI = 1.49-1.52), hospital admissions (IRR = 1.86, 95% CI = 1.84-1.88), MVA injuries (IRR = 2.08, 95% CI = 1.81-2.39), and fractures (IRR = 1.21, 95% CI = 1.18-1.23) than periods of adherence. CONCLUSION: These findings suggest that nonadherence to antiepileptic drugs can have serious or fatal consequences for patients with epilepsy. COMMENTARY P atients with epilepsy have a three-fold higher risk of dying than the general population (1) . Some of the causes cannot be foreseen or prevented, while others, such as suicide or complications of status epilepticus that is triggered by poor antiepileptic drugs (AEDs) compliance, are causes of death that can be averted. As shown in the study by Faught and colleagues, poor AED adherence is associated with a three-fold higher risk of dying, while an average of 12% of all deaths in people with epilepsy are caused by suicide (2) .
There are several reasons, inconspicuous or not, for poor AED compliance, some with obvious solutions and others for which solutions may seem to be more elusive. For example, forgetting a treatment dose is common among people regularly taking any type of medication. The solution is obvious: use of a pillbox. High costs of medication have become a more frequent cause for poor compliance. Patients lower the dose of the AED or intentionally miss a dose to delay running out of medication. An open discussion with patients regarding their ability to afford the prescribed AED is necessary during this period of economic crisis. Indeed, solely for financial reasons, some patients are requesting that their neurologist change the prescribed AED to generic formulations or even to first generation AEDs.
Toxicity to AEDs is one of the strongest predictors of poor quality of life among people with epilepsy (3) and ultimately becomes a cause of poor AED compliance. This problem can be easily averted by educating patients on potential adverse events at the time of prescribing a new AED and in case of their occurrence, by adjusting the AED dose or considering its replacement with another medication. Furthermore, to facilitate the identification of AED-related common adverse events, patients can be asked at each visit to complete the Adverse Event Profile, a 17-item self-report screening instrument developed specifically for patients taking this class of medications (4) .
Similarly, the presence of comorbid mood disorders can contribute to poor compliance, by making patients feel hopeless/helpless about their life, seizure disorder, and futile about treatment efficacy. Mood disorders can worsen cognitive functions, including memory, which obviously will enhance the propensity to forget to take prescribed AEDs (5) . Clearly, their early identification and aggressive treatment is an obvious solution to the poor compliance associated with these comorbid disorders. Given that major depressive disorders occur in the lifetime of 30% of patients with epilepsy, clinicians must screen for this condition in every patient (6) . The Neurological Disorders Depressive Inventory for Epilepsy (NDDI-E), a six-item self-report screening instrument, was developed specifically to identify major depressive episodes in patients with epilepsy. It takes 3 minutes to complete. A score of greater than 15 is strongly suggestive of a positive diagnosis (7) .
Among the more inconspicuous causes of poor AED compliance is the patient's difficulty accepting a diagnosis of epilepsy, particularly when denial is used as a coping mechanism to deal with the explicit obstacles and unspoken fears associated with seizures in one's life. Unspoken fears include the fear of dying as a consequence of a seizure, but more generally, may relate to the patient's loss of predictability regarding physical safety. The latter issue is frequently the first serious mental health-related consequence of an epilepsy diagnosis and may be unrecognized by patients and family members alike. Failure to come to terms with the loss of predictability can have long-term consequences. For patients, it may be expressed as avoidant behavior or present with the development of episodes of anxiety and depression, contributing to poor AED compliance. Among family members, loss of predictability can result in overprotection of the patient or rejection of the diagnosis (patients may perceive this attitude as rejection of themselves). Unfortunately, clinicians treating epilepsy seldom discuss such feelings of loss with patients, although these emotions can effec-tively be addressed with awareness of them and encouragement to mourn the loss, just as one morns the loss of a loved one.
Dying from a seizure is a fear that patients and family members often dare not ask about it or do not think is a potential complication of epilepsy. Furthermore, sudden unexpected death in epilepsy (SUDEP), which accounts for approximately 2% of deaths in population-based cohorts of epilepsy and up to 25% of deaths in cohorts of more severe epilepsy, is associated with poor AED compliance (8) . The risk of SUDEP is seldom discussed with patients, and currently much controversy surrounds the issue of when and whether to bring it to the attention of patients. The dilemma focuses on the pros and cons of an early discussion of SUDEP with patients with epilepsy (9) . Given the data from Faught's study, the risk of death associated with poor AED compliance-of which SUDEP is one potential consequence-would favor an early discussion. Furthermore, information on SUDEP is easily found on various web pages dedicated to epilepsy. Failure to prepare patients to deal with these facts carries the potential of having a devastating effect on their mental well-being. In summary, death from poor AED compliance can and should be prevented: discussions with patients must encompass the obvious and less obvious causes, which the clinician is responsible for bringing up during office visits.
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